MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

Начало・Списък с акции・Kura Oncology Inc

Kura Oncology Inc

Затворен

СекторЗдравеопазване

8.85 0.68

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

8.61

Максимум

8.89

Ключови измерители
By Trading Economics
Приходи	-6.9M -81M
Продажби	-3.4M 17M
Марж на печалбата	-467.23
Служители	260
EBITDA	-12M -86M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+213.56% upside

Дивиденти
By Dow Jones
Следващи печалби	30.04.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-5.4M 750M
Предишно отваряне	8.17
Предишно затваряне	8.85

Настроения в новините

By Acuity

22%

78%

70 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

5.575 / 6.6 Подкрепа & съпротива

Kura Oncology Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9.04.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9.04.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9.04.2026 г., 23:14 ч. UTC

Пазарно говорене

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9.04.2026 г., 23:14 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

9.04.2026 г., 23:07 ч. UTC

Пазарно говорене

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9.04.2026 г., 22:54 ч. UTC

Пазарно говорене

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9.04.2026 г., 22:31 ч. UTC

Значими събития в новините

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9.04.2026 г., 22:31 ч. UTC

Значими събития в новините

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9.04.2026 г., 20:57 ч. UTC

Значими събития в новините

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9.04.2026 г., 20:55 ч. UTC

Печалби

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9.04.2026 г., 20:55 ч. UTC

Печалби

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9.04.2026 г., 20:55 ч. UTC

Печалби

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

9.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.04.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9.04.2026 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9.04.2026 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Rowan Digital Infrastructure Announces Strategic Recapitalization

9.04.2026 г., 20:25 ч. UTC

Придобивния, сливания и поглъщания

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9.04.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

9.04.2026 г., 19:30 ч. UTC

Значими събития в новините

How Digital Currencies Have Helped Iran -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Kura Oncology Inc Прогноза

Ценова цел

By TipRanks

213.56% нагоре

12-месечна прогноза

Среден 27.75 USD 213.56%

Висок 40 USD

Нисък 15 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Kura Oncology Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Kura Oncology Inc през последните 3 месеца.

Техническа оценка

By Trading Central

5.575 / 6.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

70 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.